Data from the REPRIEVE trial suggest there is only a minimal increased risk of diabetes with statins among people with HIV, and in specific, limited groups
Researchers from Massachusetts General Hospital, a founding member of the Mass General Brigham healthcare system, have found evidence that diabetes develops predominantly among people with HIV with metabolic risk factors such as prediabetes and elevated body mass index. The findings were consistent for participants treated with pitavastatin and those treated with placebo, suggesting that statins had a minimal effect on risk of new-onset diabetes. The findings are published in Annals of Internal Medicine.
Read the full press release here.
